Novas formas comerciais de anfotericina B
Palavras-chave:
anfotericina B, infecções, micosesResumo
A anfotericina B permanece como o padrão ouro para o tratamento de infecções fúngicas invasivas. Para melhorar a eficácia terapêutica desse fármaco e reduzir sua toxicidade aguda e crônica, diversas formulações lipídicas de anfotericina B foram desenvolvidas, entre elas: anfotericina B lipossômica (AmBisome®), complexo lipídico de anfotericina B (ABLC, Abelcet®) e dispersão coloidal de anfotericina B (ABCD, Amphocil®). Essas novas formulações são efetivas em várias infecções fúngicas sistêmicas, incluindo candidíase, aspergilose invasiva, mucormicose, criptococose, fusariose, sendo também eficientes no tratamento de leishmaniose. As três formulações apresentam baixa toxicidade renal, sendo mais seguras que a anfotericina B convencional. Raros são os trabalhos que comparam as formulações lipídicas. Estudos de triagem clínica em ampla escala podem esclarecer a eficácia relativa em várias formas de infecções fúngicas. A presente revisão analisa os dados disponíveis na literatura, faz uma comparação entre as três formulações lipídicas e discute a questão custo e benefício do tratamento para o paciente.
Downloads
Referências
Korolkovas A, França FFC. Dicionário terapêutico. Rio de Janeiro: Guanabara Koogan; 2003.
Larabi M, Gulik A, Dedieu JP, Legrand P, Barrat G, Cheron M. New lipid formulation of amphotericin B: Spectral and microscopic analysis. Biochim Biophys Acta. 2004; 1664(2):172-81.
Bekersky 1, Fielding RM, Buell D, Lawrence 1. Lipid-based amphotericin B formulations: from animais to man. Pharm Sei Technol Today. 1999; 2(6):230-6.
Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Therap. 1999; 24(4):249-57.
Khoo SH, Bond J, Denning DW. Administering amphotericin B: a practical approach. J Antimicrob Chemother. 1994; 33(2):203-13.
Tavares W. Manual de antibióticos e quimioterápicos antiinfecciosos. 2ed. São Paulo: Atheneu; 1996.
Hillery AM. Supramolecular lipidic drug delivery systems: From laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv Drug Dei Rev.1997; 24:345-63.
Barrat GM. Therapeutic applications of colloidal drug carriers. Pharm Sei Technol Today. 2000; 3(5): 163-71.
New RRC. Liposomes: A practical approach. New York: Oxford University Press; 1990.
Bellmann R, Egger P, Djanani A, Wiedermann CJ. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. lnt J Antimicrob Agent. 2004; 23(1):80-3.
Williams K, Kearns G. Lipid amphotericin preparations. Pediatr lnfect Dis J. 2000; 19(6):567-9.
Andres E, Tiphine M, Letscher-Bru V, Herbrecht R. Nouvelles formes lipidiques de l'amphotéricine B. Revue de la littérature. Rev Méd Interne. 2001; 22(2):141-50.
Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, et ai. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994; 38(4):713-8.
Bekersky 1, Boswell GW, Hiles RM, Fielding RM, Buell DN, Walsh TJ. Safety and toxicokinetics of intravenous lipossomal amphotericin B (Ambisome) in beagle dogs. Pharm Res. 1999; 16(11):1694-701.
Bekersky 1, Boswell GW, Hiles RM, Fielding RM, Buell DN, Walsh TJ. Safety and toxicokinetics, and tissue distribuition of ling-term intravenous lipossomal amphotericin B (Ambisome): A 91-day study in rats. Pharm Res. 2000; 17(2):1494-502.
Bekersky 1, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (Ambisome) and Amphotericin B Deoxycholate in Humans. Antimicrob Agents Chemother. 2002; 46(3):828-33
Klastersky J. Empirical antifungai therapy, lnt J Antimicrob Agents. 2004; 23(2):105-12.
Prentice HG, Hann IM, Herbrecht R. A randomized comparison of liposomal versus conventional amphotericin for treatment of pyrexia of unknown origin in neutropenic patients. Br Haematol. 1997; 98(3):711-18.
Walsh TJ, Finburg RW, Arndl C, Hiemenz J, Schwartz C, Bodensteiner D, et ai. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med.1999; 340(1O): 764-71.
Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 1O years of use. lnt J Antimicrob Agents. 2001; 17(3) 161-9.
Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et ai. A randomized, double-Blind comparative triai evaluating the safety of liposomal amphotericin B versus Amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin lnfect Dis. 2000; 31(5):1155-63
Slavin MA, Szer J, Grigg AP, Roberts AW, Seymour JF, Sasadeusz J, et ai. Guidelines for the use of antifungai agents in the treatment of invasive Candida and mould infections. lntern Med J. 2004; 34(4):192-200.
Laing RBS, Milne LJR, Leen CLS, Malcom GP, Steers AJW. Anaphylactic reactions to liposomal amphotericin. Lancet. 1994; 344(8923):682.
Vaidya SJ, Seydel C, Patel SR, Ortin M. Anaphylactic reaction to liposomal amphotericin B. Ann Pharm. 2002; 36(9):1480-1.
Lampo N, Spiliopoulos A, Licker M, Tschopp JM. Management of postpneumonectomy Aspergillus empyema extending into the thoracic wall: A plea for radical surgery and caution when using lipossomal amphotericin B. lnteractive Cardiovasc Thorac Surg. 2003; 2:682-4.
Janknegt R, de Marie S, Bakker-Woudenberg LAJM, Crommelin DJA. Liposomal and Lipid formulations of amphotericin B. Clin Pharm. 1992; 23(4):279-91.
Kan V, Bennett J, Amanthea M, Smolskis M, McManus E, Grasela D, et ai. Comparative safety, tolerance and pharmacokinetics of amphotericin B lipidic complex and amphotericin B desoxycholate in healthy male volunteers. J lnfect Dis. 1991; 164(2):418-25.
Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et ai. Amphotericin B Lipid Complex for invasive fungai infections: Analysis of safety and efficacy in 556 cases. Clin lnfect Dis. 1998; 26(6):1383-96.
Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis. 1998; 31(5):780-5.
Walsh TJ, Seibel NL, Arndt C, Harris RE, Dinubile MJ, Reboli A, et ai. Amphotericin B lipid complex in pediatric patients with invasive fungai infections. Pediatr lnfect Dis J 1999; 18(8):702-8.
Sharkey PK, Graybill JR, Johnson ES, Haurath SG, Pollard RB, Kolokathis A, et ai. Amphotericin B lipid complex compareci with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinic lnfect Dis.1996; 22(2):315-21.
Abelcet lnjection Drug lnformation [homepage on the Internet]. 2004 [cited 2004 Jul 8]. Available from: http://www.drugs.com/PDR/Abelcet_lnjection.html
White MH, Bowden RA, Sandlre ER, Graham ML, Noskin GA, Wingard JR, et ai. Randomized, Double-Blind Clinicai Triai of Amphotericin B Colloidal Dispersion vs Amphotericin B in the Empirical Treatment of Fever and Neutropenia. Clin lnfect Dis. 1998; 27(2) 296-302
Bowden R, Chandraseker P, White MH, Li X, Pietrelli L, Gurwith M. A Double-Blind Randomized Controlled Triai of Amphotericin B Colloidal Dispersion versus Amphotericin B for the treatment of invasive aspergilose in immunocompromised patients. Clin lnfect Dis. 2002; 35(4):359-66.
Amphotec Drug lnformation [homepage on the Internet]. 2004 [cited 2004 Jul 9]. Available from: http://www.drugs.com/PDR/Amphotec. html
Fukui H, Koike T, Takashi N, Saheki A, Sonoke S, Tomii Y, et ai. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations. lnt J Pharm. 2003; 267(1-2):101-12.
Boswell GW, Buell D, Bekersky 1. Ambisome (Liposomal Amphotericin B): a comparative. Rev J Clin Pharm. 1998; 38(7): 583-92.
Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations - Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet: Againsmt systemic urine aspergilose. Antimicrob Agents Chemother. 2004; 48(3):1047-50
